NCT02631421|Completed
Loading search results
Sponsor study identifier
observational
15
1 country
1
Study Start
January 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2019
Actual (reported)Study Completion
June 2019
Actual (reported)Right ventricular (RV) failure is the predominant cause of death in pulmonary arterial hypertension (PAH). No RV-specific therapies are available, in part because the underlying mechanisms of RV dysfunction are poorly understood. Given the heart's preference for fatty acids (FA) as an energy source, a deeper understanding of FA metabolism may shed light on RV adaptation to elevated afterload in PAH. The purpose of this study is to test the hypothesis that defects in fatty acid metabolism are common in PAH and contribute to RV failure. The investigators will measure peripheral and transcardiac lipid and glucose metabolites in PAH patients in comparison with patients with pulmonary venous hypertension and no evidence of pulmonary hypertension. The investigators will also correlate metabolites with concurrent measurement of right ventricular function.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 12, 2014
Actual (reported)January 2015
Date type not reportedThis date has not been verified as actual or estimated.
December 16, 2015
Actual (reported)June 2019
Actual (reported)June 2019
Actual (reported)Peripheral blood oleoylcarnitine in PAH versus control
At time of clinic visit, within 24 hrs prior to right heart catheritization
Percent change across the cardiac circulation of oleate and the glucose/lactate ratio.
The combination of these findings will indicate if there is a decreased reliance on FAO and and increased glycolysis
At time of right heart catheterization
Correlation of oleoylcarnitine, other acylcarnitines and free fatty acids with the homeostatic index of insulin resistance, tricuspid annular plane systolic excursion, and six minute walk distance
At time of clinic visit, within 24hrs prior to right heart catheritization
Correlation of the trans-cardiac gradient of oleate and lactate/glucose with right ventricular ejection fraction on cardiac MRI and six minute walk distance.
At time of right heart catheterization
Measurement of trans-cardiac acylcarnitines
At time of right heart catheterization
Measurement of trans-cardiac and trans-pulmonary glucose metabolites
At time of right heart catheterization
Measurement of trans-cardiac and trans-pulmonary lipid metabolites
At time of right heart catheterization
Clinical diagnosis of pulmonary arterial hypertension
Patients referred for right heart catheterization who do not have PAH
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
PAH
Vanderbilt Univeristy
Nashville, Tennessee, 37203, United States
Plasma
Evan Brittain, MD, MSCI
Vanderbilt Univerisy
15 participants (actual enrollment reported by the registry).
First Submitted
December 12, 2014
First Posted
December 16, 2015
Study Start
January 2015
Date type not reportedThis date has not been verified as actual or estimated.
Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial
Contact the study team to confirm eligibility.
Primary Completion
June 2019
Actual (reported)Study Completion
June 2019
Actual (reported)Last Updated
July 16, 2019
Record last verified: 2019-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: